Click to Watch the Video Interview
Many strategies to improve implementation of hypertension guideline recommendations have been proposed [Whelton, 2023]. Additionally, the use of monotherapy to treat hypertension may be evolving [Jackson, 2023; Cooper-DeHoff, 2021] as access to effective and affordable single pill antihypertensive combination drug therapies forms part of the latest ESH guidance [Mancia, 2023; Whelton, 2023] and combination therapies are increasingly effective in lowering BP compared with monotherapies [Jackson, 2023; Wald, 2009]. Accurate BP measurements with home or ambulatory monitoring is a key recommendation for the primary prevention of hypertension which are also highlighted in US (American College of Cardiology, American Heart Association) and European (ESH and ESC) guidelines [Whelton, 2023; Sorte, 2023]. Additionally, the importance of identifying and treating nocturnal hypertension (BP ≥120/70 mmHg) is highlighted in the ESH 2023 guidelines [Mancia, 2023]. Multi-component primary care interventions for hypertension have had some recent success in reducing cardiovascular disease (CVD) incidence, morbidity and mortality [Chay, 2024]. For this intervention to effectively operate, factors such as capacity, leadership and sufficient external support play an important role [Hespe, 2022]. Further ways to deliver interventions are being considered [Maroney, 2023]. Non-medical interventions, such as the low-calorie Dietary Approaches to Stop Hypertension [DASH] diet, have proven to be effective in reducing CVD risk factors [Le Goff, 2023]. Combining this diet along with other lifestyle changes, effectively reduced CVD risk factors [Whelton, 2023; Mancia, 2023].
At the end of this video interview, learners will:
Cardiologists, internists, general practitioners, nurse practitioners and other HCPs who manage patients with CVD and hypertension.
English with voice over into Russian and Chinese
Implementation and intervention strategies to improve BP control and reduce CVD
Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996. His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 60 countries and has published 482 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.
Atul Pathak, MD, PhD, is Director of the National Institute of Cardiology, Cardiac Surgery and Interventional Cardiology (INCCI) in Luxembourg and Professor of Medicine. A cardiologist and pharmacologist by training, he has spent his career working in research, clinical practice and hospital management. After completing his university studies in Toulouse, where he headed several units specialising in cardiovascular pharmacology, hypertension and heart failure, he went on to become head of the Cardiovascular Medicine Department at the Princess Grace Hospital Centre in Monaco, before joining the INCCI in 2025 in Luxembourg. A recognised specialist in arterial hypertension and heart failure, Prof. Pathak has held several leading positions in European and French learned societies, notably as President of the French Society of Hypertension and member of the Executive Council of the European Society of Hypertension. Author of more than 400 scientific publications and involved in the development of international recommendations, he is committed to developing innovative strategies to improve the quality and efficiency of cardiovascular care. Through his experience at the crossroads of clinical practice, research and healthcare organisation, he brings unique expertise on the levers of efficiency in healthcare.
Stay in the know with our CME updates